ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
CTNNB1	1499	12111402	-	Mutation	-	-	10 simple hyperplasia + 7 complex hyperplasia + 8 atypical hyperplasia	20 endometrial cancer; 11 simple endometrial hyperplasia + 9 complex endometrial hyperplasia	-	-	Sapporo Medical University Hospital	-	1 (n=16); 2 (n=3); 3 (n=1)	[1] Molecular alteration of the beta-catenin gene occurs in atypical hyperplasia or cancer; rather than in simple or complex hyperplasia without atypia; during endometrial carcinogenesis. [2] Fourteen of the 25 (56.0%) endometrial hyperplasia samples; 12 (60.0%) endometrial cancers; and 11 (55.0%) associated hyperplasias of the 20 endometrial cancers associated with hyperplasia showed nuclear localization of beta-catenin. Mutation in exon 3 of the beta-catenin gene was found in 2 of the 20 endometrial cancer samples; however; it was not found in the 25 endometrial hyperplasias or the 20 associated hyperplasias. [3] 14 of the 25 endometrial hyperplasia samples (56.0%) showed nuclear localization of b-catenin by immunohistochemistry.	Mutation of beta-catenin gene in endometrial cancer but not in associated hyperplasia	Medical Electron Microscopy	35(1):9-15	2002
CTNNB1	1499	12379748	Endometrial Adenocarcinoma and Serous Carcinoma	-	-	-	-	34 (17 Endometrial Adenocarcinoma and 17 Serous Carcinoma)	-	-	-	III (n=17)	-	[1] The expression of b-Catenin in high-grade endometrial cancers is strongly associated with histological subtype. [2] Nuclear expression of beta-catenin was observed in 8 of 17 (47%) endometrioid adenocarcinomas but in none of the serous carcinomas (P = .003). [3] There was a tendency of strong -catenin expression being associated with weak E-cadherin expression.	Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype	Modern Pathology	15(10):1032-7	2002
CTNNB1	1499	15051772	-	Down regulation/ Down expression	-	-	-	286	-	-	-	I (n=52); II (n=125); III (n=109)	-	[1] Reduced membranous expression of ß-catenin (53%) was found significantly more often among tumors with vascular invasion (P < .001); deep myometrial invasion (P = .002); and high FIGO stage. low expression was more frequent in tumors showing solid growth more than 50% of the tumor area (P = .002) and a diffusely infiltrative growth pattern (P = .005). Nuclear ß-catenin expression was detected in 27% of the endometrioid tumors. The percentage of tumor cells with nuclear ß-catenin expression varied from 5% to 90%; and often was found in areas with squamous differentiation.	Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer.	Journal of Clinical Oncology	22(7):1242-52	2004
CTNNB1	1499	18949382	-	Down regulation/ Down expression	-	-	-	-	-	-	Shandong Tumor Hospital; China	-	-	[1] The microarray study shows that this gene is down-regulated by 0.144 fold in the tumor associated endometrium.	Gene alterations in tumor-associated endothelial cells from endometrial cancer.	International Journal of Molecular Medicine	22(5):619-32	2008